As a main component of DZF, berberine has the hypoglycemic, hypolipidemic, and insulin sensitizing effect (Yin et al., 2008; Zhang et al., 2008; Wang et al., 2011; Pirillo and Catapano, 2015), attenuating hepatic steatosis (Sun et al., 2018), and activates AMPK and GLUT4 in the skeletal muscle (Lee et al., 2006). Here, INS is linked to fatty liver disease.